These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


143 related items for PubMed ID: 8423888

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Bromocriptine versus levodopa in early Parkinson's disease.
    Ramaker C, van Hilten JJ.
    Cochrane Database Syst Rev; 2000; (3):CD002258. PubMed ID: 10908538
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Bromocriptine versus levodopa in early Parkinson's disease.
    van Hilten JJ, Ramaker CC, Stowe R, Ives NJ.
    Cochrane Database Syst Rev; 2007 Oct 17; 2007(4):CD002258. PubMed ID: 17943771
    [Abstract] [Full Text] [Related]

  • 8. Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study.
    Przuntek H, Welzel D, Gerlach M, Blümner E, Danielczyk W, Kaiser HJ, Kraus PH, Letzel H, Riederer P, Uberla K.
    J Neural Transm (Vienna); 1996 Oct 17; 103(6):699-715. PubMed ID: 8836932
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Does combined levodopa and bromocriptine therapy in Parkinson's disease prevent late motor complications?
    Alarcon F, Cevallos N, Lees AJ.
    Eur J Neurol; 1998 May 17; 5(3):255-263. PubMed ID: 10210840
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK, Goetz CG, Leurgans S, Fan W, Nguyen T, Hsu A.
    Clin Neuropharmacol; 2009 May 17; 32(4):189-92. PubMed ID: 19620848
    [Abstract] [Full Text] [Related]

  • 16. The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease.
    Rabey JM, Schwartz M, Graff E, Harsat A, Vered Y.
    Clin Neuropharmacol; 1991 Dec 17; 14(6):514-22. PubMed ID: 1773422
    [Abstract] [Full Text] [Related]

  • 17. Bromocriptine for levodopa-induced motor complications in Parkinson's disease.
    van Hilten JJ, Ramaker C, Van de Beek WJ, Finken MJ.
    Cochrane Database Syst Rev; 2000 Dec 17; 1998(2):CD001203. PubMed ID: 10796755
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 8.